Early effects of first‐line treatment with anti‐interleukin‐6 receptor antibody tocilizumab for chronic active antibody‐mediated rejection in kidney transplantation-Reference-Cited by-同舟云学术

Early effects of first‐line treatment with anti‐interleukin‐6 receptor antibody tocilizumab for chronic active antibody‐mediated rejection in kidney transplantation

Published:2020-06-16 Issue:8 Volume:34 Page:
ISSN:0902-0063
Container-title:Clinical Transplantation
language:en
Short-container-title:Clin Transplant

Author:

Lavacca Antonio¹,Presta Roberto¹,Gai Chiara²,Mella Alberto¹,Gallo Ester¹,Camussi Giovanni²,Abbasciano Isabella¹,Barreca Antonella³,Caorsi Cristiana⁴,Fop Fabrizio¹,Messina Maria¹,Rossetti Maura¹,Biancone Luigi¹^ORCID

Affiliation:

1. Renal Transplant Center “A. Vercellone”, Nephrology, Dialysis and Renal Transplant Division Department of Medical Sciences “Città della Salute e della Scienza” Hospital University of Turin Turin Italy

2. Stem Cell Laboratory Department of Medical Sciences University of Turin Turin Italy

3. Division of Pathology Department of Medical Sciences “Città della Salute e della Scienza” Hospital University of Turin Turin Italy

4. Department of Medical Sciences Immunogenetic and Transplant Biology Center “Città della Salute e della Scienza” Hospital University of Turin Turin Italy

Funder

Università degli Studi di Torino

Publisher

Wiley

Subject

Transplantation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ctr.13908

Reference51 articles.

1. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure

2. Successful Treatment of Chronic Antibody-Mediated Rejection With IVIG and Rituximab in Pediatric Renal Transplant Recipients

3. Rituximab and Intravenous Immunoglobulin Treatment of Chronic Antibody-Mediated Kidney Allograft Rejection